SynthesisDigestive diseases and sciences2011
Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials.
Synthesis in Digestive diseases and sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03543566 (Antimuscarinic Medication for Urgency Urinary Incontinence in Women With Dual Incontinence), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antimuscarinic Medication for Urgency Urinary Incontinence in Women With Dual Incontinence (Darifenacin for Treatment of Women With Dual Incontinence)
Who cites it
29 citing papers in PubMed, 67 citations in OpenAlex.
- Transcutaneous neuromodulation versus oxybutynin for neurogenic detrusor overactivity in persons with spinal cord injury: A randomized, investigator blinded, parallel group, non-inferiority controlled trial.The journal of spinal cord medicine · 2025Trial
- Trial
- The urologist's role in bowel management of adult spina bifida: a narrative review.Translational andrology and urology · 2024Review
- Bowel and Bladder Dysfunction after SCI: A Comparison between India and Canada.Topics in spinal cord injury rehabilitation · 2024Article
- Effect of darifenacin on fecal incontinence in women with double incontinence.International urogynecology journal · 2021Observational
- Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis.The Journal of international medical research · 2021Article
- Clinical features and relative factors of constipation in a cohort of Chinese patients with Parkinson's disease.World journal of gastrointestinal pharmacology and therapeutics · 2021Article
- The long-lasting post-stimulation inhibitory effects of bladder activity induced by posterior tibial nerve stimulation in unanesthetized rats.Scientific reports · 2020Article
- Management of constipation in patients with Parkinson's disease.NPJ Parkinson's disease · 2018Review
- Female Functional Constipation Is Associated with Overactive Bladder Symptoms and Urinary Incontinence.BioMed research international · 2017Article
- An update on the use of transdermal oxybutynin in the management of overactive bladder disorder.Therapeutic advances in urology · 2016Review
- Disorders of gastrointestinal hypomotility.F1000Research · 2016Review
- Comparative functional selectivity of imidafenacin and propiverine, antimuscarinic agents, for the urinary bladder over colon in conscious rats.Naunyn-Schmiedeberg's archives of pharmacology · 2015Article
- Effect of anticholinergics on the overactive bladder and bowel domain of the electronic personal assessment questionnaire (ePAQ).International urogynecology journal · 2015Article
- A prospective, comparative study of the occurrence and severity of constipation with darifenacin and trospium in overactive bladder.Journal of clinical and diagnostic research : JCDR · 2015Article
- Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.Korean journal of urology · 2013Review
- How to treat the frail elderly: The challenge of multimorbidity and polypharmacy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2013Review
- Experience with imidafenacin in the management of overactive bladder disorder.Therapeutic advances in urology · 2013Article
- Are solifenacin and ramosetron really ideal to treat irritable bowel syndrome?Journal of neurogastroenterology and motility · 2012Article
- Antimuscarinic treatment in overactive bladder: special considerations in elderly patients.Drugs & aging · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnticholinergic drugs are commonly prescribed for symptomatic treatment of overactive bladder (OAB). While recent meta-analyses have characterized the prevalence of dry mouth among patients utilizing OAB medications, prevalence of constipation has not been systematically reviewed.
aimsTo provide an effect measure for constipation associated with anticholinergic OAB drugs versus placebo.
methodsA meta-analysis of trials with darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium was conducted. All randomized, placebo-controlled studies of anticholinergic OAB drugs published in English language and identified in Medline and Cochrane databases were considered for inclusion in this meta-analysis. Those meeting predetermined design characteristics and having sufficient duration (≥2 weeks) were included. Constipation-related data from all included studies were abstracted.
resultsOne hundred two English-language, randomized, placebo-controlled trials were originally identified. Thirty-seven studies were ultimately included in the analysis, involving 19,434 total subjects (12,368 treatment+7,066 placebo patients). The odds ratios for constipation compared with placebo were as follows: overall [odds ratio (OR) 2.18, 95% confidence interval (CI)=1.82-2.60], tolterodine (OR 1.36, 95% CI=1.01-1.85), darifenacin (OR 1.93, 95% CI=1.40-2.66), fesoterodine (OR 2.07, 95% CI=1.28-3.35), oxybutynin (OR 2.34, 95% CI=1.31-4.16), trospium (OR 2.93, 95% CI=2.00-4.28), and solifenacin (OR 3.02, 95% CI=2.37-3.84).
conclusionsOur results demonstrate that patients prescribed anticholinergic OAB drugs are significantly more likely to experience constipation. Differences in muscarinic receptor affinities among individual agents may possibly account for the modest variation in constipation rates observed; however, such a determination warrants additional research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.